mp3 dönüştür

We are experts in myeloma…
it’s all we do

 

Our singular focus on myeloma ensures that we bring unparalleled expertise and dedication to everything we do

 

From actionable insights to strategic engagement with leading KOLs and community clinicians, our full suite of  services empowers you to lead in the myeloma market

Everything you need to navigate the myeloma market

Insights

MYInsights provides real-time insights to data being presented at conferences or from the latest publications. Gain an understanding of how the experts view the data.

Data Compass conference reports. Collecting insights at medical conferences shouldn’t be hard. MYELOMA360 makes it easy!

Engagements

MYBoard is a new format for Advisory Boards.

In place of single company events, MYBoard is an independent full day advisory board fully managed by MYELOMA360, with four 2-hour time slots for multiple companies, allowing for a focused, efficient, dedicated session to generate insights around your strategic objectives.

Strategy & Consulting

We are a team of seasoned biopharmaceutical specialists dedicated to helping companies strategize and plan their marketing, clinical development and medical affairs activities.

Our expertise is focused in myeloma across the full development lifecycle, allowing us to provide tailored solutions to drive your company’s success.

Everything you need to navigate the myeloma market

Latest insights

Myeloma News

Electrical therapy shows promise for metastatic pancreatic cancer

A type of electrical therapy called Tumor Treating Fields (TTFields), given in combination with chemotherapy and other medication, may help prevent disease progression in people with metastatic pancreatic cancer, according to data from a Phase 2 clinical trial. “We...

Outcomes of hematopoietic stem cell transplantation in patients aged 70 years and older

Source: Myeloma : nature.com subject feeds Post Content Read More

Glioblastoma treatment GLIX1 enters human trials

GLIX1, a treatment for recurrent and progressive glioblastoma and other high-grade gliomas, has begun human testing in a Phase 1/2a clinical trial, said BioLineRx, which is developing the treatment in a joint venture along with Hemispherian. The trial (NCT07464925)...

FDA fast tracks treatment for advanced, resistant ovarian cancer

The U.S. Food and Drug Administration (FDA) has granted fast-track designation to the experimental therapy ZW191 as a potential treatment for hard-to-manage ovarian cancer. The designation covers ZW191’s potential use in ovarian cancer that is advanced or metastatic —...

Pharmacokinetics of CAR T cells in multiple myeloma – the good, the bad, and the ugly

Source: Myeloma : nature.com subject feeds Post Content Read More
Latest Data

Latest Publications

Prophylactic Immunoglobulin Supplementation for Infection Prevention in Multiple Myeloma: An Updated Systematic Review and Meta-Analysis

Clin Lymphoma Myeloma Leuk. 2026 Mar 6:S2152-2650(26)00066-2. doi: 10.1016/j.clml.2026.03.002....

CLO26-105: Gut Microbiota and Multiple Myeloma: A Systematic Review of Risk, Prognosis, and Therapeutic Implications

J Natl Compr Canc Netw. 2026 Mar 31;24(3.5):CLO26-105. doi: 10.6004/jnccn.2025.7191. NO ABSTRACT...

Risk factors for infections in patients with multiple myeloma: a systematic review and meta-analysis

Front Oncol. 2026 Mar 12;16:1726340. doi: 10.3389/fonc.2026.1726340. eCollection 2026. ABSTRACT...

Non-ICANS Neurologic Toxicity after BCMA CAR T: A systematic review and meta-analysis of 4630 multiple myeloma patients

Blood Adv. 2026 Mar 26:bloodadvances.2026019617. doi: 10.1182/bloodadvances.2026019617. Online...

Systematic literature review of secondary primary malignancies related to a CAR-T treatment in patients with multiple myeloma, lymphoma or leukemia

Cancer Treat Res Commun. 2026 Feb 28;47:101161. doi: 10.1016/j.ctarc.2026.101161. Online ahead of...

Email

info@myeloma360.com

bahisliongalabet1xbet